Non-Cystic Fibrosis Bronchiectasis (NCFB) - 2020 Pipeline Insight Report - ResearchAndMarkets.com
The "Non-Cystic Fibrosis Bronchiectasis (NCFB) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Non-Cystic Fibrosis Bronchiectasis (NCFB) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis (NCFB) market. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape is provided, which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment guidelines.
The assessment part of the report embraces in-depth Non-Cystic Fibrosis Bronchiectasis (NCFB) commercial assessment and clinical assessment of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline products from the pre-clinical developmental phase to the marketed phase.
In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis (NCFB) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB) with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment.
- Non-Cystic Fibrosis Bronchiectasis (NCFB) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Non-Cystic Fibrosis Bronchiectasis (NCFB) market.
Scope of the Report
- The Non-Cystic Fibrosis Bronchiectasis (NCFB) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Cystic Fibrosis Bronchiectasis (NCFB) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Non-Cystic Fibrosis Bronchiectasis (NCFB) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Cystic Fibrosis Bronchiectasis (NCFB).
Key Topics Covered
1. Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis (NCFB)
2.1. Overview
2.2. History
2.3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Diagnosis
2.6.1. Diagnostic Guidelines
3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Current Treatment Patterns
3.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment Guidelines
4. Non-Cystic Fibrosis Bronchiectasis (NCFB) - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Non-Cystic Fibrosis Bronchiectasis (NCFB) companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Non-Cystic Fibrosis Bronchiectasis (NCFB) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Non-Cystic Fibrosis Bronchiectasis (NCFB) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Non-Cystic Fibrosis Bronchiectasis (NCFB) Late Stage Products (Phase-III)
7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Discontinued Products
13. Non-Cystic Fibrosis Bronchiectasis (NCFB) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Companies
15. Non-Cystic Fibrosis Bronchiectasis (NCFB) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs
18. Non-Cystic Fibrosis Bronchiectasis (NCFB) Future Perspectives
19. Non-Cystic Fibrosis Bronchiectasis (NCFB) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Companies Mentioned
- Zambon S.p.A.
- Chiesi Farmaceutici S.p.A.
- Alaxia SAS
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wig53i
View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005077/en/